Antibiotic de-escalation as a hospital stewardship strategy in adults with Pneumonia: A mini review

Broad-spectrum antibiotics are frequently initiated in hospitalized adults with pneumonia before apathogen is identified. Antibiotic de-escalation is the subsequent narrowing or simplification of therapywhen clinical and diagnostic information indicates that broader coverage is no longer required. This review examines whether de-escalation is associated with reduced antibiotic exposure without aconsistent increase in treatment failure or mortality.

Relevant clinical studies, one randomized trial of rapid molecular testing, one published systematicreview, and major stewardship guidelines were reviewed. Sources were selected for relevance to adultpneumonia rather than through a registered systematic search, and findings were compared qualitatively.

Observational evidence associates de-escalation with fewer days of antibiotic therapy and, in somecohorts, with lower rates of Clostridioides difficile infection and shorter hospitalization. Treatmentfailure has not differed significantly in the largest nosocomial-pneumonia cohort reviewed. Rapid molecular testing increases the frequency of de-escalation by shortening time to a microbiologic result,although overall antibiotic duration may not decline. A meta-analysis of culture-negative pneumoniareported lower in-hospital mortality with de-escalation, but the estimate is heterogeneous and derivedfrom observational studies.

The available literature supports routine reassessment of empiric broad-spectrum therapy. De-escalation is appropriate when the patient is clinically stable and the available data permit narrowing. Itshould not be applied automatically. Differences in pneumonia classification, de-escalation definitions,and study design limit generalization.